April 19, 2017, Oslo, Norway – In January 2016, Aker BioMarine filed a U.S. lawsuit against Olympic Holding, Rimfrost, Emerald Fisheries and their partners Avoca and Bioriginal.
In the suit, filed in the District Court of Delaware, Aker BioMarine claimed that the parties used Aker BioMarine’s patented processes and offered its patented krill oil products for sale. Aker BioMarine also filed a complaint with the International Trade Commission (ITC) to stop these infringing activities.
Since the ITC investigation started, Olympic Holding and Emerald Fisheries have gone bankrupt and the “Juvel” krill harvesting vessel has been seized by creditors. Last week, Avoca and Aker BioMarine settled their patent dispute on terms that are confidential between the parties.
Considering these developments, Aker BioMarine has asked the ITC to discontinue its investigation. Aker BioMarine will continue to pursue its claim for patent infringement and damages from Rimfrost and Bioriginal in the pending District Court case in Delaware.
For media inquiries, please contact:
Marketing & Communications Director, Superba™
Aker BioMarine is a biotech innovator and Antarctic krill fishing company dedicated to improving human and planetary health. The company develops krill-based ingredients for nutraceutical, aquaculture, and animal feed applications. The company’s fully transparent value chain stretches from sustainable krill fishing in pristine Antarctic waters through its Montevideo logistics hub, Houston production plant, and all the way to customers around the world. Aker BioMarine is fully owned by Aker ASA, an industrial pioneer since its establishment in 1841.
SuperbaTM Krill is a pure, natural source of the health-promoting EPA & DHA omega-3 essential fatty acids and the naturally occurring antioxidant astaxanthin. The uniqueness of SuperbaTM Krill is that the omega-3 fatty acids are provided in phospholipid form. In vitro, in vivo and human clinical research has demonstrated the safety and efficacy of SuperbaTM Krill.